Cell line · CVCL_1893
Y-79
Cancer cell line, Homo sapiens. Retinoblastoma. 39 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. Y-79. Cell lines, record CVCL_1893. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1893
On this page
Cell line
As Cellosaurus gives it.
- Name
- Y-79
- Accession
- CVCL_1893
- RRID
- RRID:CVCL_1893
- Synonyms
- Y79, GM01232, GM01232E
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 2Y6M
- Category
- Cancer cell line
- Diseases
- Retinoblastoma (NCIt C7541); Retinoblastoma (ORDO Orphanet_790)
- Derived from
- Eye, globe (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers39
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Anti-PD-L1 scFv-secreting fifth-generation GD2-CAR T cells enhance antitumor function against GD2-low retinoblastoma. | Mol Ther Nucleic Acids | 2026 | Its Methods give the RRID and name the line | PubMed | |
| B7-H3 and GD2 overexpression as immunotherapeutic targets in retinoblastoma. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting TUBG1 in RB1-negative tumors. | FASEB J | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Netrin-1 and UNC5B Cooperate with Integrins to Mediate YAP-Driven Cytostasis. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma. | Commun Biol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas with Local and Systemic Delivery of CAR T Cells. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| In vivo CRISPR screening directly targeting testicular cells. | Cell Genom | 2024 | Its Methods give the RRID and name the line | PubMed | |
New retinoblastoma (RB) drug delivery approaches: anti-tumor effect of atrial natriuretic peptide (ANP)-conjugated hyaluronic-acid-coated gold nanoparticles for intraocular treatment of chemoresistant RB. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Ceftriaxone exerts antitumor effects in MYCN-driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Inhibiting the activation of MAPK (ERK1/2) in stressed Müller cells prevents photoreceptor degeneration. | Theranostics | 2022 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 39
See all 39 papersRelatives8
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | RB355 | CVCL_S611 | Has a recorded problem | Cell lines |
| Derived from it | Ubigene Y-79 SFXN5 KO | CVCL_E1F7 | Cell lines | |
| Derived from it | WERI-Rb-27 | CVCL_S610 | Has a recorded problem | Cell lines |
| Derived from it | Y-79 CDDP-R | CVCL_B7IF | Cell lines | |
| Derived from it | Y-79 Eto-R | CVCL_B7IG | Cell lines | |
| Derived from it | Y79-6 | CVCL_VA40 | Cell lines | |
| Derived from it | Y79-Luc | CVCL_ZF06 | Cell lines | |
| Derived from it | Y79/EDR | CVCL_A5SR | Cell lines |
Cell banks16
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | HTB-18 | ATCC | |
| AddexBio | C0029001/4898 | Cellosaurus | |
| BCRC | 60422 | BCRC | |
| BCRJ | 0380 | BCRJ | |
| CLS | 300382 | CLS | |
| Coriell | GM01232 | Coriell | |
| DSMZ | ACC-246 | DSMZ | |
| ECACC | 86093003 | ECACC | |
| IBRC | C11182 | Cellosaurus | |
| ICLC | HTL99029 | ICLC |
1 to 10 of 16
See all 16 cell banksData dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1893
GET https://conductscience.org/api/cell-lines/v1/CVCL_1893/papers?page=2